Sign in

    Bing Zhao

    Research Analyst at China Renaissance

    Bing Zhao is an Equity Research Analyst at China Renaissance Securities, specializing in healthcare sector coverage with a particular focus on biopharmaceutical and life sciences companies. He has covered companies including I-Mab and BeOne Medicines, providing detailed research and engaging directly with management through earnings call participation. Bing Zhao began his analyst career at China Renaissance in the late 2010s and has contributed to research recognized by institutional clients, but publicly available performance rankings or quantitative track records are limited. While Bing Zhao is listed as a covering analyst by multiple companies, there is no public record of FINRA registration or specific professional securities licenses.

    Bing Zhao's questions to I-Mab (IMAB) leadership

    Bing Zhao's questions to I-Mab (IMAB) leadership • H1 2023

    Question

    Bing Zhao asked how the potential approval of Astellas' zolbetuximab might impact the clinical plan for givastomig and questioned the rationale for selecting a 4-1BB bispecific target over others.

    Answer

    CMO John Hayslip and President Andrew Zhu highlighted givastomig's differentiation, citing its efficacy across a broad range of Claudin expression levels and a more favorable safety profile with less GI toxicity than competing monoclonal antibodies. This positions it strongly for the first-line setting. The 4-1BB target was chosen for its ability to conditionally activate the immune system within the tumor microenvironment, thereby minimizing systemic side effects.

    Ask Fintool Equity Research AI